Osteoarthritis Trial, Recruiting NCT05887284 Sponsor: University of Erlangen-Nürnberg Medical School Condition: Osteoarthritis
Back to Osteoarthritis

Osteoarthritis Trial, Recruiting

NCT05887284
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed with osteoarthritis (joint wear and tear) in one of the following areas: fingers or wrists, elbow, shoulder, knee, or ankle and foot joints
  • You have never before received low-dose radiation therapy on the affected joint
  • You are willing to attend all treatment and follow-up appointments, and you live close enough to the trial site to do so

Who may not be able to join:

  • You currently have or have previously had a cancer diagnosis
  • You are able to become pregnant or father a child, and you are not willing or able to use reliable contraception throughout the treatment period
  • You currently have an ongoing problem with misuse of drugs, medications, or alcohol
  • Your doctor believes that taking part in the trial would not be in your best interests, for example if it would mean temporarily stopping important medications you rely on
  • Your osteoarthritis diagnosis is not fully confirmed or there is uncertainty about the diagnosis of the joint being treated
  • You have previously had radiation therapy as a treatment for cancer

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 19 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Oliver Ott, Prof. Dr, Department of Radiation Oncology, Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg

Phone: +49 9131 85

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
University of Erlangen-Nürnberg Medical School
Registry
ClinicalTrials.gov
Start date
1 July 2023
Est. completion
30 September 2026

Where this trial is recruiting

🇩🇪 Germany

Primary endpoints

Improvement in general pain (determined by visual analog scale (VAS) score) after LDRT compared to the placebo.; Identification of immunological changes, which contribute to the success of therapy and are specifically found in the test group.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov